Press Release

Press Release

New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale

Jan 11, 2021

Illumina Connected Analytics: Connect, see, and read data directly in the cloud

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment.

“Illumina Connected Analytics has appeared at a critical time for our research group—just as our analysis needs have started exceeding our existing capability,” noted Dan Spiegelman from Montreal Neurological Institute and Hospital in Canada. “The scalability of the joint genotyping tools has enabled us to perform analyses larger than any we have attempted before, in a surprisingly short timeframe. This platform not only meets our current needs but will allow us room to grow our analyses to petabase scale.”

Accessible through a web portal or through a rich set of APIs, ICA reduces the extra work and possible human-error associated with combining multiple datasets, through a direct sequencer-to-platform transfer of data onto the private Illumina cloud. With security and compliance at the core, the data is able to be seen, read, automatically processed, analyzed and shared securely. Optimized for high-throughput, ICA also supports the complex storage, aggregation, and querying of multi-omic sequencing and array data from around the world.

“In our mission to understand Leukemia and bring those benefits to patients, we need a solution that provides security, privacy, scalability, speed, and cost effectiveness for our workflows,” said Niroshan Nadarajah, Head of Bioinformatics, at the Munich Leukemia Laboratory in Munich, Germany. “Illumina Connected Analytics enables us to meet those goals by shifting our informatics to the cloud—positioning us for further collaboration and growth as we push the boundaries of advanced diagnostics.”

Harnessing the technology brought from the 2020 acquisition of BlueBee, ICA is advancing Illumina’s cloud portfolio by giving users the flexibility to run custom analyses and access industry leading options, including award-winning Illumina informatics solutions, such as the DRAGENTM Bio-IT Platform. Designed for the unprecedented scale in the next decade of sequencing, ICA uniquely provides customers the ability to manage the vast amount of genomic data being generated on our installed base of more than 17,000 sequencing systems today and into the future.

“The launch of Illumina Connected Analytics honors our steadfast commitment to empowering customers with their data insights by delivering a secure data exchange private cloud designed for genomics,” said Susan Tousi, Chief Product Officer at Illumina. “Coupled with some of the best data science, machine learning, and tertiary analysis tools that will be provided on the platform, this software will enable our customers to truly explore their data, discover insights and unlock the power of the genome.”

Illumina Connected Analytics will be available on January 28, 2021. For more information, visit our website.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Juliet Cunningham

Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111

Source: Illumina, Inc.